Monitor EMA review timelines and potential approval decision for AVT29, which could unlock a significant biosimilar market opportunity in Europe. Also watch for competitive biosimilar filings from other developers targeting the Eylea 8 mg segment.
Price Chart
Executive Summary
Alvotech and Advanz Pharma announced the first known regulatory submission worldwide for AVT29, a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL), filed as a line extension to the existing European marketing authorization for Mynzepli (aflibercept 2 mg). The 8 mg formulation accounted for approximately 57% of combined global Eylea 2 mg and 8 mg sales by value in Q2 2026, up from ~30% in Q2 2025, highlighting the commercial importance of this high-dose segment. This milestone positions Alvotech at the forefront of the next wave of aflibercept biosimilars, though AVT29 remains investigational and has not yet received regulatory approval.
Key Facts
- First known regulatory submission worldwide for a proposed biosimilar to Eylea 8 mg (aflibercept 114.3 mg/mL).
- AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli (aflibercept 2 mg).
- The 8 mg formulation accounted for approximately 57% of combined global Eylea 2 mg and 8 mg sales by value in Q2 2026, up from approximately 30% in Q2 2025.
- Mynzepli (AVT06, aflibercept 2 mg) received European Commission approval in August 2025.
- Alvotech is responsible for development and commercial supply of AVT06 and AVT29; Advanz Pharma handles registration and commercialization in Europe.
Financial Impact
No financial figures provided in the filing; the 8 mg formulation represents a growing share (~57% in Q2 2026) of a multi-billion-dollar Eylea franchise, but AVT29 is pre-revenue and unapproved.
Risk Factors
- AVT29 is investigational and has not received regulatory approval; biosimilarity has not yet been established by regulatory authorities.
- Regulatory delays or negative EMA opinion could impair commercial prospects.
- Competition from other biosimilar developers targeting the same high-dose aflibercept market.
- Reliance on Advanz Pharma for European commercialization; partnership execution risk.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006617 |
| Document: f6k_101426.htm | 0001171843-26-006617 |
| Document: 0001171843-26-006617-index-headers.html | 0001171843-26-006617 |
| Document: 0001171843-26-006617-index.html | 0001171843-26-006617 |
| Document: 0001171843-26-006617.txt | 0001171843-26-006617 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $5.12 | awaiting T+20 | — | $4.62 (−9.77%) |
Oct 14, 2026 12d ago | 6-K | $5.17 | awaiting T+20 | — | $4.62 (−10.64%) |
Oct 7, 2026 19d ago | 6-K | $5.85 | awaiting T+20 | — | $4.62 (−21.03%) |
Oct 5, 2026 21d ago | 6-K | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Oct 5, 2026 21d ago | Press Release | $6.11 | awaiting T+20 | — | $4.62 (−24.39%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.62 (−10.98%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.62 (+4.29%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.62 (−8.20%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.62 (+30.88%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.62 (+33.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers